Molteni Purchase Agreement (Details Textual) - 3 months ended Mar. 31, 2018 € in Millions, $ in Millions |
USD ($) |
EUR (€) |
EUR (€) |
|---|---|---|---|
| Purchase Agreement [Line Items] | |||
| Proceeds from Sale of Productive Assets | $ 2.4 | € 2.0 | |
| Potential Payments Receivable | $ 5.5 | € 4.5 | |
| Revenue Recognition, Milestone Method, Description | (i) a €1.0 million milestone payment upon the issuance by the European Medical Authority (“EMA”) of the MAA and (ii) an aggregate of € 2.0 million of milestone payments upon approval of the product reimbursement price in certain key countries, provided that the payments in (i) and (ii) are subject to a 50% reduction if the EMA marketing authorization is not received on or prior to September 30, 2019 and shall not be payable in the event such authorization is not received on or prior to March 31, 2020. Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties. | (i) a €1.0 million milestone payment upon the issuance by the European Medical Authority (“EMA”) of the MAA and (ii) an aggregate of € 2.0 million of milestone payments upon approval of the product reimbursement price in certain key countries, provided that the payments in (i) and (ii) are subject to a 50% reduction if the EMA marketing authorization is not received on or prior to September 30, 2019 and shall not be payable in the event such authorization is not received on or prior to March 31, 2020. Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties. | |
| Cost Approach Valuation Technique [Member] | |||
| Purchase Agreement [Line Items] | |||
| Estimated Selling Price | $ 1.4 | ||
| Residual Approach [Member] | Intellectual Property [Member] | |||
| Purchase Agreement [Line Items] | |||
| Finite-Lived Intangible Assets, Translation and Purchase Accounting Adjustments | $ 1.0 |